High progesterone receptor expression in prostate cancer is associated with clinical failure

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Grindstad, Thea ^a   Andersen, Sigve ^a,b   Al Saad, Samer ^a,b   Donnem, Tom ^a,b   Kiselev, Yury ^a   Melbø Jørgensen, Christian Nordahl ^a   Skjefstad, Kaja ^a   Busund, Lill Tove ^a,b   Bremnes, Roy M ^a   Richardsen, Elin ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL DENSITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECEPTOR DENSITY; RETROSPECTIVE STUDY; STROMA CELL; TISSUE MICROARRAY; TUMOR CELL; TUMOR GROWTH; CANCER GRADING; CANCER STAGING; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL; TREATMENT FAILURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 84923888535     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116691     Document Type: Article

References (46)

1. IARC IA for R on CWHO (2012) GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. GLOBOCAN. Available: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx?
2. Klotz L (2013) Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes 20. Available: http://journals.lww.com/co-endocrinology/Fulltext/2013/06000/Prostate-cancer-overdiagnosis-and-overtreatment.8.aspx.
3. Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, et al. (2014) Androgen receptor antagonists for prostate cancer therapy. Endocrine-Related Cancer. Available: http://erc.endocrinology-journals.org/content/early/2014/03/17/ERC-13-0545.abstract.
4. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RAM, et al. (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer..
5. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, et al. (2001) Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 19: 1619-1628. PMID: 11250990
6. Migliaccio A, Castoria G, Auricchio F (2007) Src-dependent signalling pathway regulation by sex-steroid hormones: Therapeutic implications. Int J Biochem Cell Biol 39: 1343-1348. doi: 10.1016/j.biocel.2006.12.009 PMID: 17329144
7. Morriss-Kay G (1991) Langman's Medical Embryology. J Anat 175: 273-274. doi: 10.1097/00006534-198801000-00024
8. Denis LJ, Griffiths K (2000) Endocrine treatment in prostate cancer. Semin Surg Oncol 18: 52-74. Available: http://www.ncbi.nlm.nih.gov/pubmed/10617897. PMID: 10617897
9. Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P, et al. (2001) Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61: 1919-1926. PMID: 11280747
10. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K (2001) Progesterone receptor expression in human prostate cancer: correlation with tumor progression. Prostate 48: 285-291. Available: http://www.ncbi.nlm.nih.gov/pubmed/11536308. PMID: 11536308
11. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, et al. (2001) A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 98: 6330-6335. doi: 10.4048/jbc.2011.14.1.20 PMID: 11371645
12. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, et al. (2013) Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. Cell 155: 1309-1322. Available: http://www.sciencedirect.com/science/article/pii/S0092867413014256. doi: 10.1016/j.cell.2013.11.012 PMID: 24315100
13. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, et al. (2001) Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 61: 5331-5335. PMID: 11454669
14. Aufrère MB, Benson H (1976) Progesterone: An overview and recent advances. J Pharm Sci 65: 783-800. Available: http://dx.doi.org/10.1002/jps.2600650602. PMID: 945344
15. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, et al. (1992) Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 147: 798-803. PMID: 1371552
16. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, et al. (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144: 735-746. PMID: 7512791
17. Brolin J, Skoog L, Ekman P (1992) Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate 20: 281-295. PMID: 1376911
18. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, et al. (2001) Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159: 79-92. PMID: 11438457
19. Wernert N, Gerdes J, Loy V, Seitz G, Scherr O, et al. (1988) Investigations of the estrogen (ER-ICA-test) and the progesterone receptor in the prostate and prostatic carcinoma on immunohistochemical basis. Virchows Arch A Pathol Anat Histopathol 412: 387-391. doi: 10.1007/BF00750267 PMID: 3125679
20. Mobbs BG, Liu Y (1990) Immunohistochemical localization of progesterone receptor in benign and malignant human prostate. Prostate 16: 245-251. PMID: 1691842
21. Luetjens CM, Didolkar A, Kliesch S, Paulus W, Jeibmann A, et al. (2006) Tissue expression of the nuclear progesterone receptor in male non-human primates and men. J Endocrinol 189: 529-539. Available: http://joe.endocrinology-journals.org/content/189/3/529.abstract. PMID: 16731784
22. Yu Y, Liu L, Xie N, Xue H, Fazli L, et al. (2013) Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. J Clin Endocrinol Metab 98: 2887-2896. Available: http://www.ncbi.nlm.nih.gov/pubmed/23666965. doi: 10.1210/jc.2012-4000 PMID: 23666965
23. Hiramatsu M, Maehara I, Orikasa S, Sasano H (1996) Immunolocalization of oestrogen and progesterone receptors in prostatic hyperplasia and carcinoma. Histopathology 28: 163-168. PMID: 8834526
24. Hobisch A, Hittmair A, Daxenbichler G, Wille S, Radmayr C, et al. (1997) Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J Pathol 182: 356-361. doi: 10.1002/(SICI)1096-9896(199707)182:3〈356::AID-PATH863〉3.0.CO;2-U PMID: 9349240
25. Castagnetta LA, Miceli MD, Sorci CM, Pfeffer U, Farruggio R, et al. (1995) Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 136: 2309-2319. PMID: 7536668
26. Helpap B, Egevad L (2009) Modified Gleason grading. An updated review. Histol Histopathol 24: 661-666. Available: http://europepmc.org/abstract/MED/19283673. PMID: 19283673
27. Epstein J (2010) An update of the Gleason grading system. J Urol 183: 433-440. Available: http://www.sciencedirect.com/science/article/pii/S0022534709027049. doi: 10.1016/j.juro.2009.10.046 PMID: 20006878
28. Chan T (2005) World Health Organization classification of tumours: Pathology & genetics of tumours of the urinary system and male genital organs. Available: http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:World+Health+Organization+Classification+of+Tumours.+Pathology+and+Genetics+of+Tumours+of+the+Urinary+System+and+Male+Genital+Organs.#0.
29. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, et al. (2002) High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 20: 2417-2428. doi: 10.1200/JCO.2002.08.159 PMID: 12011119
30. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ, et al. (2006) Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition. J Clin Oncol 24: 3973-3978. Available: http://jco.ascopubs.org/content/24/24/3973.abstract. PMID: 16921049
31. Andersen S, Richardsen E, Nordby Y, Ness N, Størkersen O, et al. (2014) Disease-specific outcomes of Radical Prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time. BMC Urol 14: 49. Available: http://www.biomedcentral.com/1471-2490/14/49. doi: 10.1186/1471-2490-14-49 PMID: 24929427
32. Yu Y, Lee JS, Xie N, Li E, Hurtado-Coll A, et al. (2014) Prostate Stromal Cells Express the Progesterone Receptor to Control Cancer Cell Mobility. PLoS One 9: e92714. Available: http://dx.doi.org/10.1371/journal.pone.0092714. doi: 10.1371/journal.pone.0092714 PMID: 24664419
33. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847. doi: 10.1038/nm0798-844 PMID: 9662379
34. Milanes-Yearsley M, Hammond MEH, Pajak TF, Cooper JS, Chang C, et al. (n.d.) Tissue Micro-Array: A Cost and Time-Effective Method for Correlative Studies by Regional and National Cancer Study Groups. Mod Pathol 15: 1366-1373. Available: http://dx.doi.org/10.1097/01.MP.0000036345.18944.22. PMID: 12481019
35. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, et al. (2007) The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 21: 359-375. doi: 10.1210/me.2006-0337 PMID: 17138644
36. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, et al. (1998) Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 17: 2008-2018. doi: 10.1093/emboj/17.7.2008 PMID: 9524123
37. Skildum A, Faivre E, Lange CA (2005) Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol 19: 327-339. doi: 10.1210/me.2004-0306 PMID: 15486045
38. Hernández-Hernández OT, González-García TK, Camacho-Arroyo I (2012) Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines. J Steroid Biochem Mol Biol 132: 127-134. doi: 10.1016/j.jsbmb.2012.04.005 PMID: 22542550
39. Dohi O, Hatori M, Suzuki T, Ono K, Hosaka M, et al. (2008) Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma. Cancer Sci 99: 518-523. doi: 10.1111/j.1349-7006.2007.00673.x PMID: 18081879
40. Hanekamp EE, Gielen SCJP, Smid-Koopman E, Kühne LCM, de Ruiter PE, et al. (2003) Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 9: 4190-4199. PMID: 14519645
41. Check JH, Dix E, Cohen R, Check D, Wilson C (2010) Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Res 30: 623-628. PMID: 20332480
42. Check JH, Dix E, Wilson C, Check D (2010) Progesterone receptor antagonist therapy has therapeutic potential even in cancer restricted to males as evidenced from murine testicular and prostate cancer studies. Anticancer Res 30: 4921-4923. PMID: 21187471
43. Lin MF, Kawachi MH, Stallcup MR, Grunberg SM, Lin FF (1995) Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate 26: 194-204. PMID: 7716084
44. El Etreby MF, Liang Y, Johnson MH, Lewis RW (2000) Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice. Prostate 42: 99-106. doi: 10.1002/(SICI)1097-0045(20000201)42:2〈99::AID-PROS3〉3.0.CO;2-I PMID: 10617866
45. Gao W, Bohl CE, Dalton JT (2005) Chemistry and structural biology of androgen receptor. Chem Rev 105: 3352-3370. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2096617&tool=pmcentrez&rendertype=abstract. PMID: 16159155
46. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, et al. (2007) Enhanced Paracrine FGF10 Expression Promotes Formation of Multifocal Prostate Adenocarcinoma and an Increase in Epithelial Androgen Receptor. Cancer Cell 12: 572-585. doi: 10.1016/j.ccr.2007.11.002 PMID: 18068633